Accumulated data has implicated IRA, or the IR total content, as an important factor in breast cancer outcome and implicates IRA as a mechanism of resistance towards therapies specifically targeting IGF-1R, namely monoclonal antibody therapeutics. This evidence concerns the gene IGF1R and breast cancer.